Brokerages Set AstraZeneca PLC (NASDAQ:AZN) Target Price at $80.00

Shares of AstraZeneca PLC (NASDAQ:AZNGet Free Report) have been given an average rating of “Hold” by the six analysts that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $80.00.

Several research analysts recently weighed in on AZN shares. Morgan Stanley started coverage on shares of AstraZeneca in a report on Tuesday, January 23rd. They set an “overweight” rating on the stock. Deutsche Bank Aktiengesellschaft lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a research report on Thursday, February 8th. HSBC started coverage on shares of AstraZeneca in a research report on Monday, December 18th. They issued a “buy” rating on the stock. Finally, Jefferies Financial Group lowered shares of AstraZeneca from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd.

Read Our Latest Research Report on AZN

Institutional Trading of AstraZeneca

A number of hedge funds and other institutional investors have recently bought and sold shares of AZN. Fairfield Bush & CO. purchased a new position in AstraZeneca in the 1st quarter worth approximately $28,000. Panagora Asset Management Inc. grew its stake in AstraZeneca by 55.1% in the 1st quarter. Panagora Asset Management Inc. now owns 11,956 shares of the company’s stock worth $793,000 after buying an additional 4,249 shares in the last quarter. BlackRock Inc. grew its stake in AstraZeneca by 22.0% in the 1st quarter. BlackRock Inc. now owns 7,466,492 shares of the company’s stock worth $495,328,000 after buying an additional 1,343,939 shares in the last quarter. Great West Life Assurance Co. Can grew its stake in AstraZeneca by 102.7% in the 1st quarter. Great West Life Assurance Co. Can now owns 525 shares of the company’s stock worth $36,000 after buying an additional 266 shares in the last quarter. Finally, Moors & Cabot Inc. grew its stake in AstraZeneca by 2.8% in the 1st quarter. Moors & Cabot Inc. now owns 10,841 shares of the company’s stock worth $719,000 after buying an additional 292 shares in the last quarter. Institutional investors own 15.68% of the company’s stock.

AstraZeneca Stock Down 1.4 %

AstraZeneca stock opened at $61.41 on Tuesday. AstraZeneca has a fifty-two week low of $60.47 and a fifty-two week high of $76.56. The stock has a market cap of $190.39 billion, a PE ratio of 31.98, a price-to-earnings-growth ratio of 1.13 and a beta of 0.52. The firm’s 50-day simple moving average is $66.43 and its 200 day simple moving average is $66.65. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.64 and a current ratio of 0.82.

AstraZeneca (NASDAQ:AZNGet Free Report) last released its quarterly earnings results on Thursday, February 8th. The company reported $0.73 earnings per share for the quarter, missing the consensus estimate of $0.74 by ($0.01). AstraZeneca had a return on equity of 30.19% and a net margin of 13.00%. The firm had revenue of $12.02 billion for the quarter, compared to analysts’ expectations of $12.07 billion. During the same quarter last year, the firm posted $0.69 earnings per share. The firm’s revenue for the quarter was up 7.3% compared to the same quarter last year. Research analysts predict that AstraZeneca will post 4.09 EPS for the current fiscal year.

AstraZeneca Increases Dividend

The company also recently announced a Semi-Annual dividend, which will be paid on Monday, March 25th. Investors of record on Friday, February 23rd will be issued a dividend of $0.965 per share. This represents a yield of 2.3%. The ex-dividend date is Thursday, February 22nd. This is a positive change from AstraZeneca’s previous Semi-Annual dividend of $0.47. AstraZeneca’s dividend payout ratio is 47.40%.

About AstraZeneca

(Get Free Report

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Recommended Stories

Analyst Recommendations for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.